View Future GrowthOncotelic Therapeutics 過去の業績過去 基準チェック /36Oncotelic Therapeuticsは72.6%の年平均成長率で業績を伸ばしているが、Biotechs業界はgrowingで29.1%毎年増加している。売上は減少しており、年平均93.4%の割合である。主要情報72.62%収益成長率75.63%EPS成長率Biotechs 業界の成長17.04%収益成長率-93.39%株主資本利益率95.15%ネット・マージンn/a前回の決算情報31 Dec 2025最近の業績更新更新なしすべての更新を表示Recent updatesOncotelic Therapeutics, Inc. announced delayed annual 10-K filingApr 01Oncotelic Therapeutics, Inc.'s Sapu Nano Launches Deciparticle Platform and Presents Clinical PipelineMar 25Oncotelic Therapeutics and Brush and Key Foundation Announce Publication in International Journal of Molecular Sciences Highlighting Context-Dependent Biomarkers in Liver and Pancreatic CancerDec 16Oncotelic and Sapu Nano Announce Deciparticle Led Biomarker Framework Identifying Tumors Most Likely to Respons to Iv Sapu003, an Intravenous Everolimus NanomedicineDec 04+ 1 more updateOncotelic and Sapu Nano Unveils Broad-Appointment of Broad-Appointment of Sapu Nano Nanomedicine Platform Capable of Formulating Multiple Hydrophobic Peptide, Macrolide, and Polyketide DrugsDec 03Oncotelic Therapeutics, Inc. announced delayed 10-Q filingNov 15Sapu Nano Unveils First-In-Human Clinical Trial of Sapu-003 at 8th Australian Translational Breast Cancer Research SymposiumOct 10Sapu Nano's Sapu003 Advances to Human Clinical Testing - Transforming Everolimus Delivery with Full Bio Availability for Breast Cancer PatientsSep 24Oncotelic Therapeutics Highlights 2 Years of Clinical and Regulatory Advancements Across Late-Stage PipelineSep 13Oncotelic Therapeutics, Inc. Provides Update on Its Clinical PipelineSep 05Oncotelic Therapeutics, Inc. Highlights Peer-Reviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer PatientsJul 17Oncotelic Therapeutics, Inc. Announces Publication of Landmark Study on TGFB2 Gene Methylation as A Positive Prognostic Marker in Pancreatic CancerJun 25Oncotelic Therapeutics, Inc. announced delayed annual 10-K filingApr 01Oncotelic Therapeutics, Inc. Announces Successful Completion of Phase 1 Trial of OT-101 and IL-2Mar 25Oncotelic Therapeutics, Inc. Implements PDAOAI PlatformJan 01Oncotelic Therapeutics, Inc. announced delayed 10-Q filingNov 15Oncotelic Therapeutics, Inc. announced delayed annual 10-K filingApr 02Oncotelic Therapeutics, Inc. Announces Linkage of Cancer and Lupus in Gliomas PatientsMar 27Oncotelic Therapeutics, Inc. announced delayed 10-Q filingAug 17Oncotelic Therapeutics, Inc. announced delayed 10-Q filingMay 16Oncotelic Announces Initiation of Clinical Study in Non-Small Lung Cell CancerFeb 07Oncotelic Therapeutics, Inc. Initiates Clinical Trials Evaluating OT-101 against Metastatic Pancreatic CancerJan 26Oncotelic Therapeutics, Inc. Presents Clinical Data of Confirming TGF-BETA>2 as the Appropriate Target for Gliomas At JCA-AACR Meeting 2022Dec 20Oncotelic Therapeutics, Inc. announced delayed 10-Q filingNov 15Oncotelic Initiates Clinical Trials Evaluating OT-101 Against Pediatric GliomasNov 09Oncotelic Therapeutics, Inc. announced delayed 10-Q filingAug 16Oncotelic Therapeutics Receives FDA Clearance for Phase 2 Clinical Trial of OT-101/Pembroluzimab Combination for Mesothelioma (M201)May 26Oncotelic Therapeutics, Inc. announced delayed 10-Q filingMay 17Oncotelic Appoints Seymour Fein M.D. as Chief Regulatory OfficerMay 05Oncotelic Therapeutics, Inc. Appoints Fatih Uckun as Chief Medical OfficerMay 04Oncotelic Therapeutics, Inc. announced delayed annual 10-K filingApr 01Oncotelic Presenting OT-101 Oncology Program at Biotechgate Digital PartneringJan 20Oncotelic Therapeutics, Inc. Initiates Phase 1 Trial Evaluating CA4P in Combination with Pembrolizumab for MelanomaJan 07Oncotelic Announces ORF8 Mutations are Driving the Evolution of the Delta and the Omicron VariantsDec 23Oncotelic Therapeutics, Inc. announced that it has received $0.5 million in funding from Talos Victory Fund, LLC, Mast Hill Fund, L.P.Dec 02+ 1 more updateOncotelic Announces Positive Topline Data for OT-101 C001 COVID StudyNov 24Oncotelic Therapeutics, Inc. Reports PulmoHealTM/ ArtiVedaTM Proven Active against Mild and Moderate COVID-19 Following the Preplanned Prospective Analysis of ARTI-19 Clinical TrialAug 25Oncotelic Therapeutics, Inc. announced delayed 10-Q filingAug 17Oncotelic Therapeutics, Inc. announced that it has received $0.6985 million in funding from Autotelic Inc.Aug 06Oncotelic Therapeutics, Inc. Closes Covid-19 Clinical Trial EarlyJun 16Oncotelic Therapeutics, Inc. announced delayed 10-Q filingMay 18Oncotelic Therapeutics, Inc. announced delayed annual 10-K filingApr 03Mateon Announces Initiation of Phase 1B Clinical Trial on OT-101/IL-2 Combination Therapy for Solid TumorsMar 16Mateon Therapeutics, Inc. Announces Enrollment Enrollment of its Sentinel Part 1 and Part 2 COVID-19Mar 10Mateon Therapeutics, Inc. and Windlas Biotech Limited Launches Pulmoheal™, A Combined Lung Therapy and Ai Telemedicine 360° SolutionFeb 23Mateon Therapeutics, Inc. Partners with The Chopra Foundation for Development of PulmoHea and ARTIVedaFeb 18Mateon Therapeutics, Inc. Announces Completion of Arti-19 and Publication of Positive Interim DataFeb 04Mateon Therapeutics, Inc. Launches its Artificial Intelligence Telemedicine Platform for Post Marketing Survey to Support the Launch of its Drug Product, PulmoHealTMFeb 02Mateon Announces Positive Interim Results from ARTI-19 Clinical Trial Evaluating Covid-19 TherapeuticJan 14Mateon Therapeutics and Windlas Biotech Enter into Definitive Agreement to Commercialze Artiveda™ Against Covid-19Nov 12Mateon Therapeutics, Inc. Announces the Receipt of Approval from Instituto Nacional De Salud (Ins), the Regulatory Agency of Peru, to Initiate the Company’s C001- Phase 2 Clinical Trial of OT-101Nov 06Mateon Therapeutics, Inc. Receives Approval from Republica Argentina for Phase 2 Global Study for OT-101Oct 20Mateon Therapeutics, Inc. Announces First Patient Enrolled in ARTI-19: A Multicenter Interventional Study of ArtiShield Against COVID-19Oct 08Mateon Therapeutics, Inc. and Windlas Biotech Limited Announce ArtiShield Is Now Approved for Manufacture and Marketing by the Ministry of AYUSHOct 06Mateon Therapeutics, Inc. announced that it has received $2 million in fundingJun 30収支内訳Oncotelic Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:OTLC 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Dec 2502493030 Sep 250-21030 Jun 250-40031 Mar 250-40031 Dec 240-50030 Sep 240-50030 Jun 240-10031 Mar 240-81031 Dec 230-81030 Sep 230-121030 Jun 230-131031 Mar 23091031 Dec 22055130 Sep 22095130 Jun 22086231 Mar 220-119331 Dec 210-95430 Sep 210-115630 Jun 210-115631 Mar 211-83631 Dec 202-105430 Sep 202-105230 Jun 202-95131 Mar 200-105131 Dec 190-73130 Sep 190-32130 Jun 190-31131 Mar 190-21131 Dec 180-101質の高い収益: OTLC 非現金収入 のレベルが高いです。利益率の向上: OTLC過去に利益を上げました。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: OTLC過去 5 年間で収益を上げており、収益は年間72.6%増加しています。成長の加速: OTLCは昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。収益対業界: OTLC昨年収益を上げたため、昨年の収益成長をBiotechs業界 ( 50.1% ) と比較することは困難です。株主資本利益率高いROE: OTLCの 自己資本利益率 ( 95.1% ) は 傑出している と考えられます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/04/30 13:30終値2026/04/30 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Oncotelic Therapeutics, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Theodore O'NeillLitchfield Hills Research, LLC
Oncotelic Therapeutics, Inc.'s Sapu Nano Launches Deciparticle Platform and Presents Clinical PipelineMar 25
Oncotelic Therapeutics and Brush and Key Foundation Announce Publication in International Journal of Molecular Sciences Highlighting Context-Dependent Biomarkers in Liver and Pancreatic CancerDec 16
Oncotelic and Sapu Nano Announce Deciparticle Led Biomarker Framework Identifying Tumors Most Likely to Respons to Iv Sapu003, an Intravenous Everolimus NanomedicineDec 04+ 1 more update
Oncotelic and Sapu Nano Unveils Broad-Appointment of Broad-Appointment of Sapu Nano Nanomedicine Platform Capable of Formulating Multiple Hydrophobic Peptide, Macrolide, and Polyketide DrugsDec 03
Sapu Nano Unveils First-In-Human Clinical Trial of Sapu-003 at 8th Australian Translational Breast Cancer Research SymposiumOct 10
Sapu Nano's Sapu003 Advances to Human Clinical Testing - Transforming Everolimus Delivery with Full Bio Availability for Breast Cancer PatientsSep 24
Oncotelic Therapeutics Highlights 2 Years of Clinical and Regulatory Advancements Across Late-Stage PipelineSep 13
Oncotelic Therapeutics, Inc. Highlights Peer-Reviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer PatientsJul 17
Oncotelic Therapeutics, Inc. Announces Publication of Landmark Study on TGFB2 Gene Methylation as A Positive Prognostic Marker in Pancreatic CancerJun 25
Oncotelic Therapeutics, Inc. Announces Successful Completion of Phase 1 Trial of OT-101 and IL-2Mar 25
Oncotelic Therapeutics, Inc. Initiates Clinical Trials Evaluating OT-101 against Metastatic Pancreatic CancerJan 26
Oncotelic Therapeutics, Inc. Presents Clinical Data of Confirming TGF-BETA>2 as the Appropriate Target for Gliomas At JCA-AACR Meeting 2022Dec 20
Oncotelic Therapeutics Receives FDA Clearance for Phase 2 Clinical Trial of OT-101/Pembroluzimab Combination for Mesothelioma (M201)May 26
Oncotelic Therapeutics, Inc. Initiates Phase 1 Trial Evaluating CA4P in Combination with Pembrolizumab for MelanomaJan 07
Oncotelic Announces ORF8 Mutations are Driving the Evolution of the Delta and the Omicron VariantsDec 23
Oncotelic Therapeutics, Inc. announced that it has received $0.5 million in funding from Talos Victory Fund, LLC, Mast Hill Fund, L.P.Dec 02+ 1 more update
Oncotelic Therapeutics, Inc. Reports PulmoHealTM/ ArtiVedaTM Proven Active against Mild and Moderate COVID-19 Following the Preplanned Prospective Analysis of ARTI-19 Clinical TrialAug 25
Oncotelic Therapeutics, Inc. announced that it has received $0.6985 million in funding from Autotelic Inc.Aug 06
Mateon Announces Initiation of Phase 1B Clinical Trial on OT-101/IL-2 Combination Therapy for Solid TumorsMar 16
Mateon Therapeutics, Inc. Announces Enrollment Enrollment of its Sentinel Part 1 and Part 2 COVID-19Mar 10
Mateon Therapeutics, Inc. and Windlas Biotech Limited Launches Pulmoheal™, A Combined Lung Therapy and Ai Telemedicine 360° SolutionFeb 23
Mateon Therapeutics, Inc. Partners with The Chopra Foundation for Development of PulmoHea and ARTIVedaFeb 18
Mateon Therapeutics, Inc. Announces Completion of Arti-19 and Publication of Positive Interim DataFeb 04
Mateon Therapeutics, Inc. Launches its Artificial Intelligence Telemedicine Platform for Post Marketing Survey to Support the Launch of its Drug Product, PulmoHealTMFeb 02
Mateon Announces Positive Interim Results from ARTI-19 Clinical Trial Evaluating Covid-19 TherapeuticJan 14
Mateon Therapeutics and Windlas Biotech Enter into Definitive Agreement to Commercialze Artiveda™ Against Covid-19Nov 12
Mateon Therapeutics, Inc. Announces the Receipt of Approval from Instituto Nacional De Salud (Ins), the Regulatory Agency of Peru, to Initiate the Company’s C001- Phase 2 Clinical Trial of OT-101Nov 06
Mateon Therapeutics, Inc. Receives Approval from Republica Argentina for Phase 2 Global Study for OT-101Oct 20
Mateon Therapeutics, Inc. Announces First Patient Enrolled in ARTI-19: A Multicenter Interventional Study of ArtiShield Against COVID-19Oct 08
Mateon Therapeutics, Inc. and Windlas Biotech Limited Announce ArtiShield Is Now Approved for Manufacture and Marketing by the Ministry of AYUSHOct 06